Compare Gilead Sciences, Inc. (GILD) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ING Groep NV — how do they compare? Gilead Sciences, Inc. trades at $133.03 (market cap $163.51B), while ING Groep NV trades at $32.82 (market cap $94.33B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and ING Groep NV pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| GILD | ING | |
|---|---|---|
Market Cap | $163.51B | $94.33B |
Sector | Health | Financials |
52-Week High | $155.80 | $33.31 |
52-Week Low | $108.22 | $22.67 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ING trades at $32.75, up 1.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows solid fundamentals with a P/E of 13.36, net income margin of 27.84%, and a consistent earnings beat history in recent quarters. Recent corporate developments include a new subscription banking model and a dividend announcement for H1-2026.
The outlook is positive with strong analyst support (62.5% Buy rating) and DCF analyses suggesting intrinsic value above current price. Key opportunities include European rate environment benefits and strategic diversification, while risks involve significant negative operating cash flows and sensitivity to macroeconomic conditions affecting the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
